- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
- Phase 4
Juvenile Idiopathic Arthritis is a most common arthritis in children. It is the inflammation of one or more joints. JIA is more common in girls. There are six different types of JIA, the symptoms may vary from type to type. Most common symptoms and signs include painful and swollen joints, stiffness in joints, joints becomes warm to touch, tiredness, relapsing fever, appearance of limp. JIA may occur because of immune system attacks or certain gene mutations. JIA is diagnosed by blood tests for Cycliccitrullinated peptide (CCP), Anti-nuclear antibody, C-reactive protein, Rheumatoid factoretc and also by CT-Scan and MRI scan. Treatment for JIA includes NSAIDS, DMARDs (Disease-modifying antirheumatic drugs), Biologics and corticosteroids, if the condition get worsen then surgery is recommended.
Key Developments:
- InNovember 2014, Novartis Pharmaceuticals commenced Phase III an open-label canakinumab (acz885) dose reduction or dose interval prolongation efficacy and safety study in patients with systemic juvenile idiopathic arthritis
- In 22013, Pfizer commenced a long-term, phase 2/3 open-label follow-up study of tofacitinib for treatment of juvenile idiopathic arthritis
Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Dynamics
Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Juvenile Idiopathic Arthritis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Juvenile Idiopathic Arthritis disease pipeline drugs development. This report studies the dynamics of the Juvenile Idiopathic Arthritis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Juvenile Idiopathic Arthritis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Segmentation
By Trial Phase
By Drugs
- Sarlumab
- Abatacept
- CertolizumabPegol
- Adalimumab
- Tocilizumab
- Canakinumab
- Tofacitinib
- Others
By Type
- Systemic JIA
- Oligoarthritis
- Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
- Psoriatic arthritis
- Enthesitis-related arthritis
- Undifferentiated arthritis
By Route of Administration
- Oral
- Parenteral
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Trial Phase |
| 2.2.2.Drugs |
| 2.2.3.Type |
| 3. Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market By Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Preclinical Trials |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Phase 1 |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Phase 2 |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Phase 3 |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Phase 4 |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market By Drugs, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Sarlumab |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Abatacept |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. CertolizumabPegol |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Adalimumab |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Tocilizumab |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Canakinumab |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Tofacitinib |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Others |
| 6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 7. Global Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Systemic JIA |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Oligoarthritis |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Psoriatic arthritis |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Enthesitis-related arthritis |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Undifferentiated arthritis |
| 7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 8. Competition Landscape |
| 8.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 8.2.1.Novartis |
| 8.2.2.Sanofi |
| 8.2.3.RegeneronPharmaceuticals |
| 8.2.4.medac GmbH |
| 8.2.5.UCB BIOSCIENCES GmbH |
| 8.2.6.F Hoffmann-La Roche |
| 8.2.7.Pfizer |
| 8.2.8.Bristol-Myers Squibb |
| 8.2.9.Eisai Co., Ltd. |
| 8.2.10.Abbott Laboratories |
| 9. Research Methodology |
| 10. Appendix and Abbreviations |
- Novartis
- Sanofi
- RegeneronPharmaceuticals
- medac GmbH
- UCB BIOSCIENCES GmbH
- F Hoffmann-La Roche
- Pfizer
- Bristol-Myers Squibb
- Eisai Co., Ltd.
- Abbott Laboratories